Voriconazole prophylaxis in lung transplant recipients

American Journal of Transplantation

Volumn 6, Issue 12, 2006, Pages 3008-3016

  Husain, S ^a   Paterson, D L ^a   Studer, S ^a   Pilewski, J ^a   Crespo, M ^a   Zaldonis, D ^a   Shutt, K ^a   Pakstis, D L ^a   Zeevi, A ^a   Johnson, B ^a   Kwak, E J ^a   McCurry, K R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Fungal infection; Lung transplantation; Prophylaxis; Voriconazole

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; AMPHOTERICIN; ASPARTATE AMINOTRANSFERASE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; DACLIZUMAB; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; ITRACONAZOLE; LIVER ENZYME; PREDNISONE; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE; VALGANCICLOVIR; VORICONAZOLE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS NIGER; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; FUNGAL COLONIZATION; HIGH RISK POPULATION; HUMAN; LIVER TOXICITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHEMOPREVENTION; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; POSTOPERATIVE COMPLICATIONS; PROBABILITY; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TRIAZOLES;

EID: 33751173454     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01548.x     Document Type: Article

References (58)

1. Gordon SM, Avery RK. Aspergillosis in lung transplantation: Incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3: 161-167.
2. Chan KM, Allen SA. Infectious pulmonary complications in lung transplant recipients. Semin Respir Infect 2002; 17: 291-302.
3. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002; 4(Suppl 3): 24-31, 24-31.
4. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915-919.
5. Husain S, Kwak EJ, Obman A et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4: 796-802.
6. Minari A, Husni R, Avery RK et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195-200.
7. Singh N, Husain S. Aspergillus infections after lung transplantation: Clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22: 258-266.
8. Kanj SS, Tapson V, Davis RD, Madden J, Browning I. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997; 112: 924-930.
9. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
10. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78: 123-138.
11. Yeldandi V, Laghi F, McCabe MA et al. Aspergillus and lung transplantation. J Heart Lung Transplant 1995; 14: 883-890.
12. Husain S, Zaldonis D, Kusne S, McCurry K. Differences in the antifungal prophylaxis strategies among North American and European centers in lung transplantation (Abstract #914). Am J Transplant 2003; 3(Suppl 5): 386.
13. Chamilos G, Kontoyiannis DP. Voriconazole-resistant disseminated Paecilomyces variotii infection in a neutropenic patient with leukaemia on voriconazole prophylaxis. J Infect 2005; 51: e225-e228.
14. Pavie J, Lacroix C, Hermoso DG et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005; 43: 4902-4904.
15. Bow EJ. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Med Mycol 2005; 43(Suppl 1): S277-S287:S277-S287.
16. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-1360.
17. Siwek GT, Dodgson KJ, Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-587.
18. Cordonnier C, Maury S, Pautas C et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943-948.
19. McCurry KR, Iacono A, Zeevi A et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus nearmonotherapy. J Thorac Cardiovasc Surg 2005; 130: 528-537.
20. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
21. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
22. Kramer MR, Denning DW, Marshall SE et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991; 144: 552-556.
23. Mehrad B, Paciocco G, Martinez FJ, Ojo TC, Iannettoni MD, Lynch JP, III. Spectrum of Aspergillus infection in lung transplant recipients: Case series and review of the literature. Chest 2001; 119: 169-175.
24. Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: Risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123: 800-808.
25. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004; 23: 1376-1381.
26. Fungal infections. Am J Transplant 2004; 4(Suppl 10): 110-134.
27. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
28. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
29. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571-1574.
30. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 2001; 20: 1274-1281.
31. Calvo V, Borro JM, Morales P et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group. Chest 1999; 115: 1301-1304.
32. Drew RH, Dodds AE, Benjamin DK, Jr., Duane DR, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232-237.
33. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-746.
34. Mattner F, Weissbrodt H, Strueber M. Two case reports: Fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004; 36: 312-314.
35. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-952.
36. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome ofmould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
37. Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37: 221-229.
38. Ally R, Schurmann D, Kreisel W et al. A randomized, double-blind, double-dummy,multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454.
39. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
40. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571.
41. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians.
42. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226-234.
43. Lehmann JB, Smallwood GA, Lesniak LA, Lawerence EC. Review of patient outcomes of aspergillus prophylaxis with voriconazole after lung transplantation. J Heart Lung Transpl 2005; 24(Suppl 1): S169.
44. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35: 1273-1275.
45. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: A dose escalation study. J Clin Pharmacol 2002; 42: 395-402.
46. Capitano B, Potoski BA, Husain S et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006; 50: 1878-1880.
47. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002; 46: 3091-3093.
48. Pai MP, Allen S. Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003; 36: 1089-1091.
49. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
50. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342: 1907-1909.
51. DeCamp MM, Jr. Inhaled cyclosporine - a breath of fresh air? N Engl J Med 2006; 354: 191-193.
52. Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 803-805.
53. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886.
54. Ioannidis JP, Haidich AB, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001; 286: 821-830.
55. Powers JH. Issues in clinical trials of prophylaxis of fungal infections. Clin Infect Dis 2004; 39(Suppl 4): S211-S217.
56. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: Twenty-second official adult lung and heart-lung transplant report - 2005.
57. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
58. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802.